Last reviewed · How we verify
Oxtriphylline (choline theophyllinate)
At a glance
| Generic name | choline theophyllinate |
|---|---|
| Sponsor | Warner Chilcott Llc |
| Drug class | choline theophyllinate |
| Target | Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1 |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxtriphylline CI brief — competitive landscape report
- Oxtriphylline updates RSS · CI watch RSS
- Warner Chilcott Llc portfolio CI